ClinicalTrials.gg

Program

napazimone

Also written as “KL1333”, “Napazimone” and “KL1333 25 mg”.

Its studies are mostly in Mitochondrial Diseases · MELAS Syndrome · Muscular Diseases, led by 2 companies.

Furthest: phase 2, since Dec 6, 20225 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Group42 open or runningphase 2since Dec 6, 2022Mar 19, 2019Oct 2027phase 2 · NCT05650229
Yungjin Pharm.10 open or runningphase 1since Feb 5, 2017Feb 5, 2017none ahead

Also a collaborator on its studies: icon-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2017First study: phase 1 study in MELAS SyndromeNew to Yungjin Pharm.Yungjin Pharm. · NCT03056209 · 60 enrolled · Korea, Republic of
  2. Mar 19, 2019Pharming Group's first study: phase 1 study in Mitochondrial DiseasesNew to Pharming GroupPharming Group · NCT03888716 · 72 enrolled · United Kingdom
  3. Nov 13, 2020Phase 1 study in Mitochondrial DiseasesPharming Group · NCT04643249 · 14 enrolled · United Kingdom
  4. Dec 6, 2022Phase 2 study in Muscular DiseasesPharming Group · NCT05650229 · 180 planned · United States, Australia, Belgium and more
  5. Feb 24, 2026Phase 2 study in Mitochondrial DiseasesPharming Group · NCT07514338 · 140 planned · United States, Belgium, Czechia and more

Ahead

  1. Oct 2027Primary completion: phase 2 study in Muscular DiseasesPharming Group · NCT05650229
  2. Mar 31, 2029Primary completion: phase 2 study in Mitochondrial DiseasesPharming Group · NCT07514338

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07514338Mitochondrial Diseases · United States, Belgium, Czechia and more2RecruitingPharming GroupMar 31, 2029140
NCT05650229Muscular Diseases · United States, Australia, Belgium and more2RecruitingPharming GroupOct 2027180
NCT04643249Mitochondrial Diseases · United Kingdom1CompletedPharming GroupDec 17, 202014
NCT03888716Mitochondrial Diseases · United Kingdom1CompletedPharming GroupMar 16, 202172
NCT03056209MELAS Syndrome · Korea, Republic of1CompletedYungjin Pharm.Apr 16, 201860

How it is read

Names in the registry

  • “KL1333”, 3 entries
  • “Napazimone”, 1 entry
  • “KL1333 25 mg”, 1 entry
  • “KL1333 50 mg”, 1 entry
  • “KL1333 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.